Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Postmortem vs. neoplastic gene expression: Clues to cancer development and therapy.

Bordonaro M.

Med Hypotheses. 2019 Aug 23;133:109381. doi: 10.1016/j.mehy.2019.109381. [Epub ahead of print]

PMID:
31476667
2.

Secondary Bile Acids and Short Chain Fatty Acids in the Colon: A Focus on Colonic Microbiome, Cell Proliferation, Inflammation, and Cancer.

Zeng H, Umar S, Rust B, Lazarova D, Bordonaro M.

Int J Mol Sci. 2019 Mar 11;20(5). pii: E1214. doi: 10.3390/ijms20051214. Review.

3.

Amlexanox and UPF1 Modulate Wnt Signaling and Apoptosis in HCT-116 Colorectal Cancer Cells.

Bordonaro M, Lazarova D.

J Cancer. 2019 Jan 1;10(2):287-292. doi: 10.7150/jca.28331. eCollection 2019.

4.

Quantum biology and human carcinogenesis.

Bordonaro M.

Biosystems. 2019 Apr;178:16-24. doi: 10.1016/j.biosystems.2019.01.010. Epub 2019 Jan 26. Review.

PMID:
30695703
5.

Hypothesis: Cancer Is a Disease of Evolved Trade-Offs Between Neoplastic Virulence and Transmission.

Bordonaro M.

J Cancer. 2018 Apr 19;9(10):1707-1724. doi: 10.7150/jca.24679. eCollection 2018. Review.

6.

Hypothesis: Induction of biomarkers for detection of colonic neoplasms.

Bordonaro M, Lazarova D.

J Cancer. 2018 Jan 1;9(1):166-173. doi: 10.7150/jca.22593. eCollection 2018.

7.

p300 Knockout Promotes Butyrate Resistance.

Lazarova DL, Bordonaro M.

J Cancer. 2017 Sep 20;8(17):3405-3409. doi: 10.7150/jca.21145. eCollection 2017.

8.

ZEB1 Mediates Drug Resistance and EMT in p300-Deficient CRC.

Lazarova D, Bordonaro M.

J Cancer. 2017 May 12;8(8):1453-1459. doi: 10.7150/jca.18762. eCollection 2017.

9.

Effects of propolis and gamma-cyclodextrin on intestinal neoplasia in normal weight and obese mice.

Cho Y, Gutierrez L, Bordonaro M, Russo D, Anzelmi F, Hooven JT, Cerra C, Lazarova DL.

Cancer Med. 2016 Sep;5(9):2448-58. doi: 10.1002/cam4.787. Epub 2016 Jun 5.

10.

In Hyperthermia Increased ERK and WNT Signaling Suppress Colorectal Cancer Cell Growth.

Bordonaro M, Shirasawa S, Lazarova DL.

Cancers (Basel). 2016 May 14;8(5). pii: E49. doi: 10.3390/cancers8050049.

11.

Determination of the Role of CBP- and p300-Mediated Wnt Signaling on Colonic Cells.

Bordonaro M, Lazarova DL.

JMIR Res Protoc. 2016 May 13;5(2):e66. doi: 10.2196/resprot.5495.

12.

Vimentin, colon cancer progression and resistance to butyrate and other HDACis.

Lazarova DL, Bordonaro M.

J Cell Mol Med. 2016 Jun;20(6):989-93. doi: 10.1111/jcmm.12850. Epub 2016 Apr 12. Review.

13.

Hypothesis: Obesity Is Associated with a Lower Mutation Threshold in Colon Cancer.

Bordonaro M, Lazarova D.

J Cancer. 2015 Jul 15;6(9):825-31. doi: 10.7150/jca.12352. eCollection 2015.

14.

CREB-binding protein, p300, butyrate, and Wnt signaling in colorectal cancer.

Bordonaro M, Lazarova DL.

World J Gastroenterol. 2015 Jul 21;21(27):8238-48. doi: 10.3748/wjg.v21.i27.8238. Review.

15.

Comprehensive suppression of all apoptosis-induced proliferation pathways as a proposed approach to colorectal cancer prevention and therapy.

Bordonaro M, Drago E, Atamna W, Lazarova DL.

PLoS One. 2014 Dec 11;9(12):e115068. doi: 10.1371/journal.pone.0115068. eCollection 2014.

16.

Experimental design to evaluate directed adaptive mutation in Mammalian cells.

Bordonaro M, Chiaro CR, May T.

JMIR Res Protoc. 2014 Dec 9;3(4):e74. doi: 10.2196/resprot.3860.

17.

Hypothesis: cell signalling influences age-related risk of colorectal cancer.

Bordonaro M, Lazarova DL.

J Cell Mol Med. 2015 Jan;19(1):74-81. doi: 10.1111/jcmm.12366. Epub 2014 Nov 11.

18.

Butyrate induced changes in Wnt-signaling specific gene expression in colorectal cancer cells.

Lazarova DL, Chiaro C, Bordonaro M.

BMC Res Notes. 2014 Apr 9;7:226. doi: 10.1186/1756-0500-7-226.

19.

Approaches that ascertain the role of dietary compounds in colonic cancer cells.

Bordonaro M, Venema K, Putri AK, Lazarova D.

World J Gastrointest Oncol. 2014 Jan 15;6(1):1-10. doi: 10.4251/wjgo.v6.i1.1. Review.

20.

Mechanisms linking dietary fiber, gut microbiota and colon cancer prevention.

Zeng H, Lazarova DL, Bordonaro M.

World J Gastrointest Oncol. 2014 Feb 15;6(2):41-51. doi: 10.4251/wjgo.v6.i2.41. Review.

21.

Modulation of Wnt Activity and Cell Physiology by Butyrate in LT97 Microadenoma Cells.

Lazarova D, Lee A, Wong T, Marian B, Chiaro C, Rainey C, Bordonaro M.

J Cancer. 2014 Feb 14;5(3):203-13. doi: 10.7150/jca.8569. eCollection 2014.

22.

Propolis augments apoptosis induced by butyrate via targeting cell survival pathways.

Drago E, Bordonaro M, Lee S, Atamna W, Lazarova DL.

PLoS One. 2013 Sep 4;8(9):e73151. doi: 10.1371/journal.pone.0073151. eCollection 2013.

23.

p300 Influences Butyrate-Mediated WNT Hyperactivation In Colorectal Cancer Cells.

Lazarova DL, Wong T, Chiaro C, Drago E, Bordonaro M.

J Cancer. 2013 Jul 18;4(6):491-501. doi: 10.7150/jca.6582. Print 2013.

24.

CBP Activity Mediates Effects of the Histone Deacetylase Inhibitor Butyrate on WNT Activity and Apoptosis in Colon Cancer Cells.

Lazarova DL, Chiaro C, Wong T, Drago E, Rainey A, O'Malley S, Bordonaro M.

J Cancer. 2013 Jul 15;4(6):481-90. doi: 10.7150/jca.6583. Print 2013.

25.

Quantum biology at the cellular level--elements of the research program.

Bordonaro M, Ogryzko V.

Biosystems. 2013 Apr;112(1):11-30. doi: 10.1016/j.biosystems.2013.02.008. Epub 2013 Mar 5.

PMID:
23470561
26.

Crosstalk between Wnt Signaling and RNA Processing in Colorectal Cancer.

Bordonaro M.

J Cancer. 2013;4(2):96-103. doi: 10.7150/jca.5470. Epub 2013 Jan 5.

27.

Tcf3 and cell cycle factors contribute to butyrate resistance in colorectal cancer cells.

Chiaro C, Lazarova DL, Bordonaro M.

Biochem Biophys Res Commun. 2012 Nov 9;428(1):121-6. doi: 10.1016/j.bbrc.2012.10.018. Epub 2012 Oct 11.

PMID:
23063976
28.

A switch from canonical to noncanonical Wnt signaling mediates drug resistance in colon cancer cells.

Bordonaro M, Tewari S, Cicco CE, Atamna W, Lazarova DL.

PLoS One. 2011;6(11):e27308. doi: 10.1371/journal.pone.0027308. Epub 2011 Nov 3.

29.

The Notch ligand Delta-like 1 integrates inputs from TGFbeta/Activin and Wnt pathways.

Bordonaro M, Tewari S, Atamna W, Lazarova DL.

Exp Cell Res. 2011 Jun 10;317(10):1368-81. doi: 10.1016/j.yexcr.2011.03.019. Epub 2011 Apr 5.

30.

Modular Cre/lox system and genetic therapeutics for colorectal cancer.

Bordonaro M.

J Biomed Biotechnol. 2009;2009:358230. doi: 10.1155/2009/358230. Epub 2009 Sep 30. Review.

31.

Role of Wnt signaling in the development of type 2 diabetes.

Bordonaro M.

Vitam Horm. 2009;80:563-81. doi: 10.1016/S0083-6729(08)00619-5.

PMID:
19251050
32.

Role of Tcf-DNA binding and the chromatin remodeling factor Brg-1 in the modulation of Wnt activity by butyrate.

Bordonaro M, Lazarova DL, Sartorelli AC.

Cell Cycle. 2008 Nov 1;7(21):3472-3. Epub 2008 Nov 5. No abstract available.

PMID:
18948734
33.
34.

Hyperinduction of Wnt activity: a new paradigm for the treatment of colorectal cancer?

Bordonaro M, Lazarova DL, Sartorelli AC.

Oncol Res. 2008;17(1):1-9. Review.

PMID:
18488710
35.

Butyrate and Wnt signaling: a possible solution to the puzzle of dietary fiber and colon cancer risk?

Bordonaro M, Lazarova DL, Sartorelli AC.

Cell Cycle. 2008 May 1;7(9):1178-83. Epub 2008 Feb 26. Review.

PMID:
18418037
36.

The activation of beta-catenin by Wnt signaling mediates the effects of histone deacetylase inhibitors.

Bordonaro M, Lazarova DL, Sartorelli AC.

Exp Cell Res. 2007 May 1;313(8):1652-66. Epub 2007 Feb 22.

37.

Modulation of Wnt-specific colon cancer cell kill by butyrate and lithium.

Bordonaro M, Lazarova DL, Carbone R, Sartorelli AC.

Oncol Res. 2004;14(9):427-38.

PMID:
15490974
38.

Pharmacological and genetic modulation of Wnt-targeted Cre-Lox-mediated gene expression in colorectal cancer cells.

Bordonaro M, Lazarova DL, Sartorelli AC.

Nucleic Acids Res. 2004 May 11;32(8):2660-74. Print 2004.

39.

Linear relationship between Wnt activity levels and apoptosis in colorectal carcinoma cells exposed to butyrate.

Lazarova DL, Bordonaro M, Carbone R, Sartorelli AC.

Int J Cancer. 2004 Jul 1;110(4):523-31.

40.

Cell type- and promoter-dependent modulation of the Wnt signaling pathway by sodium butyrate.

Bordonaro M, Lazarova DL, Augenlicht LH, Sartorelli AC.

Int J Cancer. 2002 Jan 1;97(1):42-51.

41.

Transcriptional regulation of the vitamin D(3) receptor gene by ZEB.

Lazarova DL, Bordonaro M, Sartorelli AC.

Cell Growth Differ. 2001 Jun;12(6):319-26.

42.

Down-regulation of beta-catenin TCF signaling is linked to colonic epithelial cell differentiation.

Mariadason JM, Bordonaro M, Aslam F, Shi L, Kuraguchi M, Velcich A, Augenlicht LH.

Cancer Res. 2001 Apr 15;61(8):3465-71.

43.

Colonic cell proliferation, differentiation, and apoptosis.

Augenlicht L, Velcich A, Mariadason J, Bordonaro M, Heerdt B.

Adv Exp Med Biol. 1999;470:15-22. Review. No abstract available.

PMID:
10709670
44.

Cellular mechanisms of risk and transformation.

Augenlicht LH, Bordonaro M, Heerdt BG, Mariadason J, Velcich A.

Ann N Y Acad Sci. 1999;889:20-31. Review.

PMID:
10668479
45.
46.
47.

Different mechanisms are responsible for the low accumulation of transcripts from intronless and 3' splice site deleted genes.

Bordonaro M, Nordstrom JL.

Biochem Biophys Res Commun. 1994 Aug 30;203(1):128-32.

PMID:
8074646
48.

An improved T1/A ribonuclease protection assay.

Bordonaro M, Saccomanno CF, Nordstrom JL.

Biotechniques. 1994 Mar;16(3):428-30. No abstract available.

PMID:
7514423
49.

A faster ribonuclease protection assay.

Saccomanno CF, Bordonaro M, Chen JS, Nordstrom JL.

Biotechniques. 1992 Dec;13(6):846-50. No abstract available.

PMID:
1282344

Supplemental Content

Loading ...
Support Center